Treatment with belimumab resulted in a sustained improvement of systemic lupus erythematosus disease activity in 46 percent of patients at week 52, according to a novel combined responder index in results presented today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.
Alli is the first and only FDA-approved OTC product for weight loss. It is available in stores June 15. Dr. James Anderson, UK HealthCare weight loss researcher, studied the effects of the drug on mildly to moderately overweight individuals and found it does aid weight loss.
If one part of your car isn’t properly maintained, it can affect how the entire vehicle runs ? especially if you’re taking a long trip. The same can be said for the human body. That?s why, when it comes to fitness in space, it?s important to create a program addressing the whole system, parts included.
The U.S. Food and Drug Administration said that patients who took Acomplia, also known as Zimulti, in clinical trials were more likely to suffer from suicidal thoughts or actions than those on placebo.
Medivation, Inc. (NASDAQ: MDVN) announced that the benefits of Dimebon over placebo in its double-blind, placebo-controlled Phase 2 study in mild-to- moderate Alzheimer’s disease were statistically significant on all five study endpoints at 12 months.
New research supported by the National Institutes of Health?s National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) shows that the anticonvulsant medication gabapentin, which is used for certain types of seizures, can be an effective treatment for the pain and other symptoms associated with the common, often hard-to-treat chronic pain disorder, fibromyalgia.
New data demonstrate that pramipexole (Mirapexin?/Sifrol?) is also efficacious and well-tolerated in Restless Legs Syndrome (RLS) patients with daytime RLS symptoms. The data was presented this week at the Movement Disorder Society?s (MDS) 11th International Congress of Parkinson?s Disease and Movement Disorders in Istanbul, Turkey.
GlaxoSmithKline plc announced results from an international, pivotal Phase III study of its investigational non-peptide oral platelet growth factor, Revolade? (eltrombopag). Data from this study showed that eltrombopag at 50-75mg once daily resulted in a statistically significant increase in platelet counts and also reduced bleeding in adult patients with chronic idiopathic thrombocytopenia purpura (ITP).
Male pattern hair loss (MPHL) is a condition that affects as many as 50 percent of men by the age of fifty, but according to a new study, baldness may soon be a treatable condition.
The findings in a new study on Viagra might seem obvious — the sexual satisfaction of couples involving a male with erectile dysfunction improved significantly when the man took Viagra. The novelty is that researchers cared what the woman thought.